Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

CEL-SCI CORPORATION
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases.Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).Multikine is... 
More about the company
Latest news on CEL-SCI CORPORATION
02/15CEL SCI : to Present at 2018 BIO CEO & Investor Conference
AQ
02/13CEL SCI : NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financ..
PU
02/13CEL SCI : NEW STORY CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Confe..
PU
02/12CEL SCI : reports 1Q loss
AQ
02/12CEL-SCI CORPORATION : Reports First Quarter Fiscal 2018 Financial Results
BU
02/12CEL SCI : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
02/12CEL SCI : to Present Tomorrow at 2018 BIO CEO & Investor Conference
BU
02/08CEL SCI : U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platfor..
AQ
02/05CEL SCI : to Present at 2018 BIO CEO & Investor Conference
BU
01/31CEL SCI : U.S. PATENT OFFICE ALLOWS NEW CEL-SCI PATENT FOR LEAPS VACCINE PLATFOR..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Managers
NameTitle
Geert R. Kersten Chief Executive Officer, Treasurer & Director
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Peter R. Young Independent Director
Bruno Jean Marie Baillavoine Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION25
GILEAD SCIENCES14.21%105 702
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 637